Trial Profile

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use

07 Oct 2022 Planned number of patients changed from 199 to 216.
07 Oct 2022 Planned End Date changed from 30 Sep 2023 to 31 Dec 2023.
07 Oct 2022 Planned primary completion date changed from 30 Dec 2022 to 30 Aug 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com